Thursday, May 21, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary

Market Moves

30 articles

Market Moves

Medtronic to acquire SPR Therapeutics for $650 million as top-three neuromodulation incumbents consolidate the peripheral nerve stim category

Medtronic announced on 20 May 2026 its intent to acquire SPR Therapeutics, the maker of the Sprint percutaneous peripheral nerve stimulation system, for approximately $650 million in upfront cash. The deal is the second top-three neuromodulation acquisition of a PNS specialist in seven months, after Boston Scientific completed its $533 million purchase of Nalu Medical in January 2026.

May 21

Market Moves

BlueWind Medical raises $47.8 million to scale Revi as the implantable tibial neuromodulation category separates from sacral nerve stimulation

BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale US commercialisation of Revi, the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence. The round follows three-year OASIS pivotal trial data and Medtronic's September 2025 FDA approval of its competing Altaviva tibial system.

May 20

Market Moves

MintNeuro becomes Motif Neurotech's silicon supplier as the BCI supply chain splits from vertical integration

Imperial College London spinout MintNeuro signed a multi-year commercial supply agreement on 6 May 2026 to provide its miniaturised sensing and stimulation integrated circuits to Motif Neurotech's DOT depression implant across pre-clinical, early clinical, and pivotal trial phases. The deal lands two weeks after Motif's FDA Investigational Device Exemption clearance.

May 19

Market Moves

Bioelectronic medicine reaches commercial inflection across four companies in two weeks

Spark Biomedical's CEO appointment on May 4 caps a fortnight of substantive bioelectronic-medicine milestones: SetPoint Medical's first multiple sclerosis pilot enrolment on April 30, ResMed's $340 million acquisition of Noctrix Health on the same day, and Nervonik's $52.5 million Series B on April 27. Together the four data points map onto a single maturation arc — growth-stage capital, late-stage trial expansion, commercial scaling, incumbent acquisition — and signal that the category is moving past early-clinical research into the operational layer where all four of those events run in parallel.

May 5

Market Moves

Former Harvard chemistry chair Charles Lieber leads state-funded Shenzhen BCI lab i-BRAIN

Reuters reported on April 30 that Charles Lieber, the former chair of Harvard's chemistry department convicted in December 2021 under the US China Initiative, has been appointed director of i-BRAIN, a newly established BCI institute at the Shenzhen Medical Academy of Research and Translation. The lab gives Lieber access to dedicated nanofabrication, advanced lithography, and primate research facilities at a scale unavailable to him at Harvard. The appointment lands the same week as Axoft's $55M Asian-led Series A — the capital and talent legs of the same bilateral BCI flow.

Apr 30

Market Moves

Axoft draws C.P. Group lead in $55M Series A as US BCI company runs first acute implant in Shanghai

Cambridge, Massachusetts implantable BCI company Axoft closed a $55M oversubscribed Series A on April 29, led by Thai conglomerate Charoen Pokphand's strategic arm C.P. Group Innovation with Chinese co-investors Hillhouse and Gaorong, alongside US participants Alumni Ventures and Stanford. The same announcement disclosed Axoft's first acute intraoperative test of its Fleuron polymer probe in a Shanghai patient — the first publicly confirmed clinical use of a US BCI material in China, with more Chinese trials planned this year.

Apr 29

Market Moves

Neurable launches OEM licensing programme, opening its EEG-decoder stack to consumer hardware makers

Neurable announced on April 28 that it has formally opened its consumer-EEG technology to OEM licensing, allowing third-party hardware makers to integrate the company's brain-signal-processing stack into their own products. Named integration partners include HP Inc.'s HyperX, MeSpace, iMotions, and the United States Air Force Research Laboratory. The shift recasts Neurable from a hardware company building its own consumer products into a platform layer for the broader consumer-electronics stack.

Apr 28

Market Moves

China issues guided pricing for invasive BCI procedures as provinces begin reimbursement roll-out

China's National Healthcare Security Administration has set government-guided prices of 6,000–6,600 yuan per invasive brain-computer interface implantation procedure, with Sichuan, Hubei and Zhejiang now attaching fee schedules at the provincial level — moving the country further ahead of the United States on the reimbursement layer that will decide whether BCIs scale as routine medicine.

Apr 23

Market Moves

Sabi emerges from stealth with a thought-to-text beanie and Khosla backing

California startup Sabi has exited stealth with a non-invasive EEG beanie packing up to 100,000 miniature sensors, a brain foundation model trained on 100,000 hours of neural data, and a plan to ship a consumer thought-to-text device by the end of 2026. Khosla Ventures leads.

Apr 16